Walk-in for Quality Control on 22nd July 2016 at API Ankleshwar
Cadila Healthcare Limited - Akleshwar
3 - 8 yrs
Ankleshwar
Job Description
Walk-in for Quality Control on 22nd July 2016 at Cadila Healthcare Ltd, API Ankleshwar Multi Product Plant
Here is a chance to join Zydus at our API Manufacturing located at Ankleshwar as.
Candidates having experience of 3 to 8 years in Quality Control API pharma can Walk-In for Interview along with their CVs and relevant documents at
Date : 22nd July 2016 (Friday)
Time: 09:30 AM to 04:00 PM
Venue : Plot No 291, Cadila Healthcare Ltd,
Industrial Estate , GIDC
Dist :Bharuch,
Ankleshwar,
Gujarat
 
Contact No of HR representative: 02646-660408 / 660507
Key Responsibilities are mentioned as below:
QUALITY CONTROL : Sr.Executive / Executive : M.Sc /B.Sc (Chemistry / Microbiology) with 3 - 8 years of hands on experience and relevant exposure in handling instruments like HPLC, GC, UV , wet lab, micro lab and chemical analysis of Raw Material . Must be familiar with cGMP requirements. Shop floor Operation in API / Bulk Drug Manufacturing.
Candidates having experience of working in regulatory approved plants and possesses sound knowledge of documentation, cGMP and SAP will be preferred.
Those who are unable to attend the Personal Interview may send their resume through e-mail at reema.patel@zydusmail.com
Please mention the position applying for on the top of envelope or subject in case of e-mail.
Preference will be given to candidates having API - Pharmaceutical Industries experience.
Company Profile:
Cadila Healthcare Limited - Akleshwar
Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. From a turnover of Rs. 250 crores in 1995, the group posted revenues of over Rs. 8600 crores in FY15. The group had posted a turnover of Rs. 4600 crores in FY 11, making it a billion dollar company. Recently, the group launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis.
Zydus is also the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia. The Zydus group was one amongst the top five companies worldwide at the FT ArcelorMittal Boldness in Business Awards 2014 in the Developing Markets category and was declared as the 'Emerging Company of the Year' by the Economic Times Awards for Corporate Excellence 2010. The group aims to be a leading global healthcare provider with a robust product pipeline and aspires to post revenues of Rs. 10000 crore by 2015-16 and be a research-based pharmaceutical company by 2020.
Zydus is also the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia. The Zydus group was one amongst the top five companies worldwide at the FT ArcelorMittal Boldness in Business Awards 2014 in the Developing Markets category and was declared as the 'Emerging Company of the Year' by the Economic Times Awards for Corporate Excellence 2010. The group aims to be a leading global healthcare provider with a robust product pipeline and aspires to post revenues of Rs. 10000 crore by 2015-16 and be a research-based pharmaceutical company by 2020.
Posts
